“South Africa’s Department of Health has successfully rolled out Lenacapavir, a twice‑yearly injectable HIV prevention drug, with more than 55,000 people initiated across six provinces since June 2026. The program prioritizes pregnant and breastfeeding mothers, representing a landmark step in reducing HIV transmission and strengthening public health.”
South Africa, a nation long at the forefront of the global fight against HIV/AIDS, has announced a groundbreaking achievement in its public health strategy. In September 2026, the Department of Health revealed that 55,123 individuals have been initiated on Lenacapavir, a revolutionary twice‑yearly injectable HIV prevention drug. This rollout, launched in June 2026, represents a significant leap forward in combating one of the world’s most persistent epidemics.
Background: HIV in South Africa
South Africa carries one of the highest HIV prevalence rates globally, with millions living with the virus and thousands of new infections reported annually. Traditional prevention methods, such as daily oral pre‑exposure prophylaxis (PrEP), have faced challenges with adherence. Many individuals struggle to maintain daily medication routines, leading to gaps in protection and increased risk of transmission. Lenacapavir, with its six‑month dosing schedule, offers a practical solution to these challenges, reducing the burden on patients and healthcare systems alike.
What is Lenacapavir?
Lenacapavir is a long‑acting antiretroviral drug administered every six months as PrEP. Unlike oral PrEP regimens, which require daily adherence, Lenacapavir’s twice‑yearly injection eliminates this barrier. The South African Health Products Regulatory Authority (SAHPRA) approved the drug earlier this year after rigorous clinical trials demonstrated its safety and efficacy.
Rollout Milestones
- Launch Date: June 5, 2026, by President Cyril Ramaphosa and Health Minister Dr. Aaron Motsoaledi.
- Facilities: 360 public health facilities across 24 districts in six provinces.
- Initiations: 55,123 individuals by September 7, 2026.
- Demographics: 71% female, with a majority being pregnant and breastfeeding mothers.
- Provincial Leaders: Gauteng leads with 26,357 initiations, followed by KwaZulu‑Natal (11,941), North West (4,479), Western Cape (4,446), Mpumalanga (4,294), and Eastern Cape (3,606).
Public Health Impact
The rollout addresses critical challenges in HIV prevention:
- Adherence: Daily oral PrEP often suffers from poor adherence; Lenacapavir’s twice‑yearly injection eliminates this barrier.
- Accessibility: By expanding to rural and urban facilities, the program ensures equitable access.
- Maternal Health: Prioritizing pregnant and breastfeeding mothers reduces mother‑to‑child transmission risks.
- Community Trust: Public awareness campaigns are building confidence in vaccines and prevention drugs, countering hesitancy.
Safety and Regulation
SAHPRA has approved Lenacapavir as safe and effective, following rigorous reviews of clinical and manufacturing data. Patients are advised to report any adverse events promptly, ensuring strong pharmacovigilance and clinical monitoring. Healthcare workers are closely monitoring uptake, commodity availability, service quality, and patient safety.
Government Strategy
The government has set ambitious targets:
- 1 million initiations by end of 2027
- 3 million initiations within three years
This strategy aligns with South Africa’s broader HIV prevention goals and global commitments to end AIDS as a public health threat by 2030.
Conclusion
South Africa’s rollout of Lenacapavir marks a transformative moment in HIV prevention. By prioritizing vulnerable populations, particularly pregnant and breastfeeding mothers, the country is not only reducing transmission risks but also setting a global precedent for innovative public health strategies. With ambitious targets ahead, Lenacapavir could reshape the future of HIV prevention, offering hope for millions and reinforcing South Africa’s leadership in the fight against AIDS.
